Do GLP-1 drugs thin your bones, a new way to clear aging cells and walking speed as a window on the brain, and one other thing worth your time this week.

Week of Nov 16th, 2026

This week's theme is that what you can measure from the outside, like how fast you walk or how dense your bones are, tells you a lot about what is happening underneath. We cover what GLP-1 drugs may do to bone, a new way to make aging cells easier to clear, a brain signal hiding in your walking speed, and a surprising lung and survival signal for tirzepatide. One of the four is Travis's favorite this week. Four findings, graded honestly. Here is what is worth your attention.

1. Do GLP-1 Drugs Quietly Thin Your Bones While You Lose Weight?

Weight loss usually takes some bone with it, and millions of people over 40 are now losing weight on GLP-1 drugs. Lai and colleagues published a systematic review in Archives of Osteoporosis on October 23, covering eight randomized trials and 493 adults with overweight or obesity. In the two trials with the biggest weight loss, semaglutide and liraglutide 3.0 mg, lumbar spine bone density fell by about 0.02 g/cm², and the semaglutide trial also showed higher bone breakdown markers.

Grade it as a credible warning flag built on thin evidence. Certainty was very low for every drug, each has at most five small trials, and none measured fractures. These are randomized trials, but small ones designed for other goals. The practical takeaway: if you take a GLP-1, ask your doctor about resistance training, protein, vitamin D status and whether a bone density scan makes sense. This is our favorite of the four, and here is why: it is the one finding you can act on today.

Lai, C-H, et al. Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review. Arch Osteoporos. 2026. DOI: 10.1007/s11657-026-01785-8 https://doi.org/10.1007/s11657-026-01785-8

2. Death Receptors Reveal a New Way to Clear Aging Cells

Senescent cells stop dividing, linger and drive inflammation, so clearing them safely is a central goal of longevity medicine. Gunay, Martin and colleagues at Trinity College Dublin reported in Science Advances on October 23 that senescent cells ramp up Fas and TRAIL-R2 death receptors, then survive by leaning on IAP proteins. Small-molecule IAP antagonists showed potent senolytic activity by restoring death receptor signaling through Caspase-8, in cells and animal models.

Grade it as a satisfying mechanistic win with a long runway to the clinic. This is preclinical work on therapy-induced senescence in cancer models, not natural aging in people. IAP antagonists have been tested in cancer trials, which could shorten the path, but nobody has shown they clear aging cells safely in humans. The practical takeaway: nothing to do yet, but it is a new senolytic target worth tracking.

Gunay, G, et al. Death receptors regulate entry to therapy-induced senescence and orchestrate addiction to IAPs. Sci Adv. 2026. DOI: 10.1126/sciadv.aed4541 https://doi.org/10.1126/sciadv.aed4541

3. Slower Walking Speed Tracks With Smaller Brain Regions in Early Decline

Gait speed is the cheapest test in geriatrics, and it keeps showing up as a clue to brain health. Chuang, Liang and colleagues at Kaohsiung Veterans General Hospital published a cross-sectional study in the Journal of Alzheimer's Disease on October 23, covering 234 older adults with mild cognitive impairment. On MRI, slower gait speed tracked with lower gray matter volume in the bilateral putamen and left superior frontal cortex, after adjusting for age, sex and comorbidity.

Grade it as a useful association with no proof of direction. One cross-sectional snapshot cannot say whether brain shrinkage slows the walk or the reverse, and sarcopenia status and handgrip strength showed no volume differences. The muscle mass result pointed the opposite way, and the authors urge caution. The practical takeaway: time your own usual-pace walk, and tell your doctor if it is slowing.

Chuang, T-C, et al. Changes in gray matter volume associated with gait speed and muscle mass in older adults with mild cognitive impairment. J Alzheimers Dis. 2026. DOI: 10.1177/13872877261500490 https://doi.org/10.1177/13872877261500490

4. Tirzepatide Linked to Fewer COPD Flares and Lower Mortality

COPD and type 2 diabetes often travel together, and treatments that help both are scarce. Hsu and colleagues at Chi Mei Medical Center published a TriNetX retrospective cohort study in Frontiers in Pharmacology on October 9, matching about 6,000 patients per group. Versus SGLT2 inhibitors, tirzepatide users had fewer COPD exacerbations (HR 0.73, 95% CI 0.64 to 0.82) and lower all-cause mortality (HR 0.30, 95% CI 0.23 to 0.38) over one year.

Grade it as an intriguing signal that needs a randomized trial. This is observational, and a mortality hazard ratio of 0.30 is too large to be the drug alone, which points to residual confounding such as who gets a newer prescription. Median follow-up was also shorter for tirzepatide, about 232 days versus 365. The practical takeaway: do not switch therapy on this, but expect trials in lung disease.

Hsu, W-H, et al. Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study. Front Pharmacol. 2026. DOI: 10.3389/fphar.2026.1917340 https://doi.org/10.3389/fphar.2026.1917340

Have a great week,

Travis and Winston

Medical disclaimer

The content above is for informational and educational purposes only and does not constitute medical, nutritional, or professional advice. It is not intended to diagnose, treat, cure, or prevent any disease and is not a substitute for personalized guidance from a licensed physician or other qualified healthcare provider. Individual needs and risks vary. Do not begin, stop, or modify any exercise regimen, dietary plan, medication (including tirzepatide, semaglutide, liraglutide or other GLP-1 receptor agonists, or senolytic compounds), or supplement based on this article alone. Consult your doctor first, particularly if you have or suspect a cardiovascular, metabolic, kidney, gastrointestinal, or neurological condition, take prescription medications, or are pregnant or breastfeeding. Studies summarized here vary in design and quality; preclinical and animal findings often do not translate to humans, and associations reported in observational research do not prove cause and effect.